Previous Close | 1.9100 |
Open | 1.9247 |
Bid | 1.9700 x 1400 |
Ask | 1.9900 x 1000 |
Day's Range | 1.9199 - 1.9950 |
52 Week Range | 1.4000 - 3.2900 |
Volume | |
Avg. Volume | 201,331 |
Market Cap | 167.619M |
Beta (5Y Monthly) | 1.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
Stereotaxis (STXS) delivered earnings and revenue surprises of -75% and 21.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?